- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07529808
Fas 1/2-studie av BHB810 vid avancerad gastrisk och GEJ-adenocarcinom
Fas 1/2, öppen, multricenterstudie med doseskalering och expansionsstudie av BHB810 hos deltagare med avancerad gastrisk och gastroesofageal övergångsadenokarcinom
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.
Studieöversikt
Status
Betingelser
- Magcancer
- Bukspottskörtelcancer
- Gastriskt adenokarcinom
- Gastroesofagealt adenokarcinom
- Avancerad magcancer
- Kolorektal (kolon eller rektal) cancer
- Gastrointestinala cancer
- Magcancer
- Gastrointestinal cancer Metastaserande
- Gastroesofageal Junction (GEJ) Adenocarcinom
- Gastroesofageal cancer (GC)
- Gastroesofageal Junction (GEJ) Cancer
- Gastrointestinal Adenocarcinom
- CDH17-positiva avancerade fasta tumörer
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010
- Rekrytering
- City of Hope Duarte
-
Huvudutredare:
- Dani Castillo, MD
-
Kontakt:
- Jalene Tangen
- Telefonnummer: 833-917-5715
- E-post: jtangen@coh.org
-
Santa Monica, California, Förenta staterna, 90404
- Har inte rekryterat ännu
- University of California at Los Angeles
-
Huvudutredare:
- Zev Wainberg, MD
-
Kontakt:
- Rachel Andes
- Telefonnummer: 16122 310-633-8400
- E-post: randes@mednet.ucla.edu
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Rekrytering
- NEXT Virginia
-
Huvudutredare:
- Alexander Spira, MD
-
Kontakt:
- Maybelle De La Rosa
- Telefonnummer: 703-783-4518
- E-post: mdelarosa@nextoncology.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
-
Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.
- Participants in Phase 1 Backfill Cohorts & Phase 2 must be CDH17-positive by central testing.
- Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.
-
At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
-
Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.
-
Adequate organ and marrow function as defined in the protocol
Exclusion Criteria:
-
Prior cancer treatment as follows, relative to the first planned dose of trial intervention:
- Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)
- Monoclonal antibody-based therapy (including ADCs) within 4 weeks
- Immune checkpoint inhibitors within 4 weeks
- Wide-field radiation therapy (>30% marrow-bearing bones) within 4 weeks or < 2 weeks of focal palliative radiation to nontarget lesions
-
Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)
-
Known hypersensitivity or allergic reaction to BHB810 or it's excipients
-
Left ventricular ejection fraction <50% or history of congestive heart failure Class III/IV
-
QTc interval > 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT/QTc
-
Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant
-
Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.
-
Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention
-
Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Dose Escalation and Backfill Cohorts
Dose escalation and backfill cohorts |
Every 2 weeks IV administration |
|
Experimentell: Recommended Phase 2 Dose Level 1 (RP2D1)
Dose level 1 of 2 prospective recommended phase 2 dose levels |
Every 2 weeks IV administration |
|
Experimentell: Recommended Phase 2 Dose Level 2 (RP2D2)
Dose level 2 of 2 prospective recommended phase 2 dose levels |
Every 2 weeks IV administration |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) per Common Terminology Criteria for Adverse Events v6.0 (CTCAE v6.0)
Tidsram: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
Investigate the safety and tolerability of BHB810 by evaluation of AEs, SAEs, DLTs, and clinically significant changes safety assessments, like lab tests, vital signs, and other safety assessments Phase 1 (Dose Escalation & Backfill Cohorts) and Phase 2 (Dose Optimization) DLTs apply to Phase 1 Dose Escalation Cohorts only. |
Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
|
Incidence of participants who have a dose modification of BHB810 due to toxicity
Tidsram: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
Investigate the safety and tolerability of BHB810 by assessment of dose modifications due to toxicity Phase 1 (Dose Escalation & Backfill Cohorts) |
Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
|
Overall Response Rate (ORR)
Tidsram: Screening through End of Treatment, an average of 6 months
|
Identify the recommended Phase 2 dose (RP2D) by comparing 2 doses of BHB810 by evaluating the ORR of participants according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Phase 2 (Dose Optimization) |
Screening through End of Treatment, an average of 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Clinical Benefit Rate (CBR)
Tidsram: Screening through End of Treatment, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Number of participants who achieve stable disease (SD) for at least 6 months, or PR or CR for any duration Phase 1 (Dose Escalation & Backfill Cohorts) |
Screening through End of Treatment, an average of 6 months
|
|
Duration of Response (DOR)
Tidsram: Screening through End of Treatment or last scan, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Time from PR or CR to disease progression Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Treatment or last scan, an average of 6 months
|
|
Progression Free Survival (PFS)
Tidsram: Screening through End of Treatment, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Time from first dose to first documented date of progression per RECIST v1.1 Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Treatment, an average of 6 months
|
|
Overall Survival (OS)
Tidsram: Screening through End of Study, an average of 10 months
|
Investigate preliminary antitumor activity of BHB810 Time from first dose to death from any cause Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Study, an average of 10 months
|
|
Pharmacokinetics: Area under the concentration-time curve (AUC)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to the end of a dosing interval at steady-state (AUC0-tau)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Maximum concentration of BHB810 (Cmax) Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Time to reach maximum drug concentration of BHB810 (Tmax)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to infinity (AUC0-inf)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Terminal elimination half-life (t1/2)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Volume of drug distribution during terminal phase (Vz)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Total body clearance of the drug (CL)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to last measurable concentration sample time (AUC0-last)
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Incidence of antidrug antibodies (ADAs) in blood before and after BHB810 administration
Tidsram: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the ADAs and PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Sjukdomar i det endokrina systemet
- Neoplasmer efter plats
- Tarmsjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Magsjukdomar
- Kolorektala neoplasmer
- Intestinala neoplasmer
- Neoplasmer i endokrina körtel
- Bukspottkörtelsjukdomar
- Neoplasmer, körtel och epitel
- Kolonsjukdomar
- Carcinom
- Neoplasmer
- Neoplasmer i magen
- Kolonneoplasmer
- Pankreatiska neoplasmer
- Gastrointestinala neoplasmer
- Adenocarcinom
Andra studie-ID-nummer
- BHB810-001
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .